Doctor Carlos Escobar Cervantes

Doctor Carlos Escobar Cervantes

La Paz University Hospital, Madrid (Spain)

Member of:

MD graduate at the Universidad Autonoma de Madrid. PhD grade at the Universidad de Alcalá; Doctoral Thesis qualification: A cum laude, unanimously. Specialist in Cardiology. Consultant cardiologist at Hospital La Paz (Madrid). Past President of the Clinical Cardiology group of the Spanish Society of Cardiology. Past-member of the Executive Committee of the Castilian Society of Cardiology. Member of the European Society of Cardiology (ESC). Member of the Cardiovascular Pharmacology and Drug Therapy Working Group of ESC. Referee of several national and international peer-review journals. Participation in several clinical trials and investigation projects in the fields of hypertension, heart failure, atrial fibrillation, acute coronary syndrome, and cardiometabolic disease. Over 250 papers published in national and international peer-review journals and over 40 chapters in Cardiology textbooks.

Presentations Articles

Panel discussion and Q&A

Event: ESC Preventive Cardiology 2023

Topic: Lipid-Lowering Agents

Session: Combination therapy at the heart of lipid lowering management

Access

Could combination therapy become the first step to achieving LDL-C goals in high- and very high-risk patients?

Event: ESC Preventive Cardiology 2023

Topic: Lipid-Lowering Agents

Session: Combination therapy at the heart of lipid lowering management

Access

Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry

Event: ESC Congress 2022

Topic: Cardiogenic Embolism

Session: Peripheral arterial and cerebrovascular disease 2

Access

Potential low-density lipoprotein cholesterol, cardiovascular risk and costs reduction with evolocumab: a simulation in patients with a recent myocardial infarction in Spain

Event: ESC Congress 2021 - The Digital Experience

Topic: Drug therapy

Session: Risk Factors and Prevention ePosters

Access

Resource utilization and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid-lowering therapies in Spain

Event: ESC Congress 2020

Topic: Health Economics

Session: Public Health and Health Economics ePosters

Access

Pulmonary vein isolation by high-power short-duration radiofrequency applications: short term efficacy and safety in patients with atrial fibrillation

Event: EHRA 2019

Topic: Rhythm Control, Catheter Ablation

Session: Best graded abstracts

Access

Anticoagulation and CHA2DS2-VASc score of 1 - CONTRA

Event: EHRA 2019

Topic: Treatment

Session: Knowledge gaps in clinical atrial fibrillation

Access

Doctor Carlos Escobar Cervantes

Biography

Contributor content

Panel discussion and Q&A

Could combination therapy become the first step to achieving LDL-C goals in high- and very high-risk patients?

Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry

Potential low-density lipoprotein cholesterol, cardiovascular risk and costs reduction with evolocumab: a simulation in patients with a recent myocardial infarction in Spain

Resource utilization and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid-lowering therapies in Spain

Pulmonary vein isolation by high-power short-duration radiofrequency applications: short term efficacy and safety in patients with atrial fibrillation

Anticoagulation and CHA2DS2-VASc score of 1 - CONTRA

ESC 365 is supported by